Abstract
Recombinant monoclonal antibodies break new ground in the treatment of immune-mediated nerve and muscle disorders but also of neurodegenerative diseases, in the field of neuro-oncology and in pain therapy, as they allow molecular targeting of defined cell populations or key pathophysiological molecules. However, safety risks might accompany a high efficacy. Basic understanding of this increasingly important class of agents and a steady update of knowledge, in particular on safety aspects, are therefore key requirements for responsible use based on an individual benefit-risk assessment.
MeSH terms
-
Alemtuzumab
-
Alzheimer Disease / diagnosis
-
Alzheimer Disease / drug therapy
-
Alzheimer Disease / immunology
-
Antibodies, Monoclonal / adverse effects
-
Antibodies, Monoclonal / therapeutic use*
-
Antibodies, Monoclonal, Humanized
-
Antibodies, Monoclonal, Murine-Derived
-
Antibodies, Neoplasm / adverse effects
-
Antibodies, Neoplasm / therapeutic use
-
Central Nervous System Diseases / diagnosis
-
Central Nervous System Diseases / drug therapy*
-
Central Nervous System Diseases / immunology
-
Central Nervous System Neoplasms / drug therapy
-
Clinical Trials as Topic
-
Drug Approval
-
Humans
-
Multiple Sclerosis / drug therapy
-
Natalizumab
-
Opportunistic Infections / etiology
-
Recombinant Proteins / adverse effects
-
Recombinant Proteins / therapeutic use
-
Rituximab
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Antibodies, Monoclonal, Murine-Derived
-
Antibodies, Neoplasm
-
Natalizumab
-
Recombinant Proteins
-
Alemtuzumab
-
Rituximab